false
0001618835
0001618835
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2026
EVOFEM
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-36754 |
|
20-8527075 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
7770
Regents Road, Suite 113-618
San
Diego, CA 92122
(Address
of Principal Executive Offices)
(858)
550-1900
(Registrant’s
telephone number, including area code)
Not
applicable.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| None |
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
November 13, 2026, Evofem Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the
three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information set forth in this item 2.02 and in Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934 and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Securities
Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in any such filing,
except as shall be expressly set forth by specific reference in such a filing.
Forward-Looking
Statements
This
press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements
provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.
Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,”
“hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions
or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements are based on current assumptions and involve known and unknown
risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources,
the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations,
potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, risks related to the Company’s
limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization,
together with those that are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended
December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed
with the SEC on November 13, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety
by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors
are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business
conditions.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release dated November 13, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
EVOFEM
BIOSCIENCES, INC. |
| |
|
|
| Date:
November 13, 2026 |
By: |
/s/
Ivy Zhang |
| |
|
Ivy
Zhang |
| |
|
Chief
Financial Officer |
Exhibit
99.1

Evofem
Reports Third Quarter 2026 Financial Results and Provides Business Update
SAN
DIEGO, CA, November 13, 2026 — Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results
for the three- and nine-month periods ended September 30, 2026.
Saundra
Pelletier, CEO of Evofem, said, “While third quarter net sales reflect the cumulative impact of operating without dedicated growth
capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated
across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while
continuing to support patients and healthcare providers who rely on our innovative sexual health products. We remain confident in the
long-term value of PHEXX and SOLOSEC and believe targeted investment in commercial activities would provide meaningful opportunities
to accelerate growth.”
Highlights
since July 1, 2026, include:
| ● | Income
from operations was $0.7 million for Q3 2026, compared to $1.0 million for Q3 2025. |
| | |
| ● | Net
income attributable to common stockholders was $0.9 million, or $0.01 per basic and ($0.00)
per diluted share, for Q3 2026, compared to a net loss of $1.7 million, or ($0.01) per basic
and diluted share, for Q3 2025. |
| | |
| ● | Contracted
with a second pharmaceutical manufacturer to produce PHEXX®
(lactic acid, citric acid and potassium bitartrate),
an important milestone in its strategy to support long-term growth, enhance manufacturing
flexibility, and reduce costs. |
| | |
| ● | Shipped
the 500,000th box of PHEXX in July 2026,
representing hormone-free, on-demand contraception for six million acts of sex. |
| | |
| ● | A
fifth study site was added in the ongoing investigator-led, NIH-funded Phase 4 clinical trial
evaluating the effectiveness and cost-effectiveness of SOLOSEC® (secnidazole)
2g oral granules (single-dose, one time) versus metronidazole (twice daily for seven days)
for the treatment of Trichomonas vaginalis in men and women. Study investigators hypothesize
that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC
group versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have
higher initial cost but will be more cost effective compared to multi-dose metronidazole,
largely due to lower breakthrough rates of infection.1 |
| | |
| ● | Regulatory
work is underway for SOLOSEC in Uganda, the first planned market in Sub-Saharan Africa under
our April 2026 distribution agreement with Clovis Davis Pharmaceuticals. |
Third
Quarter Financial Results
For
the three months ended September 30, 2026, net sales were $4.6 million, versus $5.0 million in the prior year period. The decrease was
primarily due to lower ex-factory sales for PHEXX in the 2026 period. Wholesalers have continued to sell through inventory purchased
in December 2025, ahead of the January 2026 price increase. Additional factors include the ongoing absence of funding
for marketing and a reduction in filled sales territories in the current quarter. This was partially offset by an increase in SOLOSEC
units sold, the wholesale average cost (WAC) increase that took effect on January 1, 2026,
and improved gross-to-net realization for both products in the 2026 period.
Total
operating expenses were $3.9 million in the third quarter of 2026, versus $4.0 million in the prior year period. The decrease was driven
by cost containment measures across all aspects of the business.
Income
from operations was $0.7 million, compared to $1.0 million in the prior year quarter.
Net
income attributable to common stockholders was $0.9 million, or $0.01 per basic and ($0.00) per diluted share, in the current period
versus a net loss attributable to common stockholders of $1.7 million, or $(0.01) per basic and diluted share, for the third quarter
of 2025.
Liquidity
Restricted cash and cash equivalents was $0.3 million as of September 30, 2026, versus $0.6 million as of December 31, 2025.
About
Evofem
Evofem
Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products:
| ● | PHEXX®
(lactic acid, citric acid, and potassium bitartrate) - the first and only hormone-free, on-demand
prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important safety
information. |
| | |
| ● | SOLOSEC®
(secnidazole) 2g oral granules - an FDA-approved oral antibiotic for the treatment of two
sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females
12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI),
in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just
one dose. Visit solosec.com to learn more and for important
safety information. |
PHEXX®
and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
Forward-Looking
Statements
This
press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements
provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.
Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,”
“hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions
or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements are based on current assumptions and involve known and unknown
risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources,
the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations,
potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, risks related to the Company’s
limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization,
together with those that are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended
December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed
with the SEC on November 13, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety
by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors
are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business
conditions.
Sources
| 1. |
National Institute of Allergy & Infectious Diseases (NIAID)
of the National Institutes of Health. Award number R01AI183266: Refining Trichomonas vaginalis treatment in women and men. |
Connect
with Us
ir@evofem.com
media@evofem.com
—
Financial Tables Follow —
EVOFEM
BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands)
| | |
As of | |
| | |
September 30, 2026 | | |
December 31, 2025 | |
| Cash and cash equivalents | |
$ | - | | |
$ | - | |
| Restricted cash and cash equivalents | |
$ | 317 | | |
$ | 578 | |
| Trade accounts receivable, net | |
$ | 3,663 | | |
$ | 12,480 | |
| Total current liabilities | |
$ | 84,776 | | |
$ | 84,820 | |
| Total stockholders’ deficit | |
$ | (83,927 | ) | |
$ | (74,336 | ) |
| Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | |
$ | 7,261 | | |
$ | 20,274 | |
EVOFEM
BIOSCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except share and per share data)
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Product sales, net | |
$ | 4,628 | | |
$ | 4,952 | | |
$ | 8,160 | | |
$ | 10,622 | |
| | |
| | | |
| | | |
| | | |
| | |
| Operating Expenses: | |
| | | |
| | | |
| | | |
| | |
| Cost of goods sold | |
| 750 | | |
| 905 | | |
| 1,671 | | |
| 2,025 | |
| Gain on change in accounting estimate on contingent royalty liability | |
| - | | |
| (1,933 | ) | |
| - | | |
| (1,933 | ) |
| Amortization of intangible asset | |
| 15 | | |
| 80 | | |
| 104 | | |
| 410 | |
| Research and development, net | |
| 341 | | |
| 470 | | |
| 1,553 | | |
| (3,819 | ) |
| Selling and marketing | |
| 1,534 | | |
| 2,391 | | |
| 5,702 | | |
| 7,616 | |
| General and administrative | |
| 1,248 | | |
| 2,088 | | |
| 5,448 | | |
| 6,296 | |
| Total operating expenses, net | |
| 3,888 | | |
| 4,001 | | |
| 14,478 | | |
| 10,595 | |
| Income (loss) from operations | |
| 740 | | |
| 951 | | |
| (6,318 | ) | |
| 27 | |
| Other income (expense), net: | |
| | | |
| | | |
| | | |
| | |
| Interest income | |
| - | | |
| 3 | | |
| 5 | | |
| 13 | |
| Other expense, net | |
| (843 | ) | |
| (682 | ) | |
| (2,193 | ) | |
| (1,944 | ) |
| Loss on debt extinguishment | |
| (405 | ) | |
| - | | |
| (2,597 | ) | |
| - | |
| Change in fair value of financial instruments | |
| 1,512 | | |
| (1,845 | ) | |
| (4,395 | ) | |
| (490 | ) |
| Total other income (expense), net | |
| 264 | | |
| (2,524 | ) | |
| (9,180 | ) | |
| (2,421 | ) |
| Loss before income tax benefit (expense) | |
| 1,004 | | |
| (1,573 | ) | |
| (15,498 | ) | |
| (2,394 | ) |
| Income tax benefit (expense) | |
| - | | |
| 4 | | |
| 1 | | |
| (3 | ) |
| Net income (loss) | |
| 1,004 | | |
| (1,569 | ) | |
| (15,497 | ) | |
| (2,397 | ) |
| Convertible and redeemable preferred stock deemed dividends | |
| (139 | ) | |
| (111 | ) | |
| (267 | ) | |
| (115 | ) |
| Net income (loss) attributable to common stockholders | |
$ | 865 | | |
$ | (1,680 | ) | |
$ | (15,764 | ) | |
$ | (2,512 | ) |
| Net loss per share attributable to common stockholders: | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) per share attributable to common stockholders: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | 0.01 | | |
$ | (0.01 | ) | |
$ | (0.12 | ) | |
$ | (0.02 | ) |
| Diluted | |
$ | (0.00 | ) | |
$ | (0.01 | ) | |
$ | (0.12 | ) | |
$ | (0.02 | ) |
| Weighted-average shares used to compute net income (loss) per share attributable to common shareholders: | |
| | | |
| | | |
| | | |
| | |
| Basic | |
| 137,337,773 | | |
| 124,385,785 | | |
| 135,989,122 | | |
| 121,037,306 | |
| Diluted | |
| 6,814,698,261 | | |
| 124,385,785 | | |
| 135,989,122 | | |
| 121,037,306 | |
To
access Evofem’s full financial results for the three-and nine-month periods ended September 30, 2026, as filed with the SEC on
Form 10-Q on November 13, 2026, please visit https://investor.evofem.com/financial-information/sec-filings/default.aspx.
###